American Society for Nutrition
PHS Financial Conflict of Interest (FCOI) Policy

1. The primary goal of this policy is to promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, and reporting of research funded under Public Health Service (PHS) grants or cooperative agreements will be free from bias resulting from Investigator financial conflicts of interest (FCOI) and to prevent an employee's activities from adversely influencing American Society for Nutrition (ASN) operations.

2. It is recognized that research-related conflicts of interest can arise from legitimate and appropriate activities including economic development, public-private interactions, and employee’s and their family’s personal business relationships.

3. This policy is implemented in accordance with 42 CFR Part 50 Subpart F - "Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought" and 45 CFR Part 94 “Responsible Prospective Contractors” as well as all other relevant policies of federal funding and oversight agencies.

Persons covered by this Policy
This policy applies to all ASN employees, including full-time, part-time, temporary, and contract employees, of ASN who participate in PHS funded research by means of a grant or cooperative agreement. This policy also applies to ASN members serving as PHS-funded Investigators on behalf of ASN.

To comply with federal FCOI regulations, ASN’s FCOI policy will be shared with all Investigators and applicable employees outlining disclosure responsibilities (listed below), and ASN’s policy and process to identify and manage FCOI and ensure compliance with all regulatory requirements. To learn more about federal FCOI regulations, visit here.

Definitions
Financial Conflict of Interest (FCOI)
Anything of monetary value, whether the value is readily ascertainable, that could directly and significantly affect the design, conduct, or reporting of PHS or National Institutes of Health (NIH)-funded research.

FCOI are not specifically limited to the interests of the individual in the role of Investigator, but also include the domestic or international financial interests of those with whom the individual has substantial shared financial interests, such as a close family member (e.g., spouse, dependent children).

Institutional responsibilities
An Investigator’s professional responsibilities on behalf of the ASN, and as defined by ASN, including, but not limited to, activities such as research, research consultation, teaching, professional practice, institutional committee memberships, and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards.

Investigator
The project director or principal Investigator (PD/PI) and any other person identified as senior/key personnel by ASN in the grant application, progress report, or any other report submitted to NIH by the ASN under the regulation, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded by PHS or NIH, or proposed for such funding, which may include, for example, collaborators or consultants.

Manage
ASN action to address a FCOI, which can include reducing or eliminating the FCOI, to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias.

Significant Financial Interest (SFI)
(1) A financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator’s spouse and dependent children) that reasonably appears to be related to the Investigator’s institutional responsibilities:

(i) Regarding any publicly traded entity, an SFI exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship); equity interest includes any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value;

(ii) Regarding any non-publicly traded entity, an SFI exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator’s spouse or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest); or

(iii) Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests.

(2) Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator and not reimbursed to the Investigator so that the exact monetary value may not be readily available), related to their institutional responsibilities; provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education. ASN’s FCOI policy will specify the details of this disclosure, which will include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. In accordance with ASN’s
FCOI policy, the designated ASN official(s) will determine if further information is needed, including a determination or disclosure of monetary value, to determine whether the travel constitutes an FCOI with the PHS-funded research.

(3) The term SFI does not include the following types of financial interests: salary, royalties, or other remuneration paid by ASN to the Investigator if the Investigator is currently employed or otherwise appointed by ASN, including intellectual property rights assigned to ASN and agreements to share in royalties related to such rights; income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles; income from seminars, lectures, or teaching engagements sponsored by a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education; or income from service on advisory committees or review panels for a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education.

Statement of General Policy
1. The design, conduct, and reporting of research funded under PHS grants or cooperative agreements should be free from bias resulting from Investigator FCOI.

2. To provide a reasonable expectation of achieving the goal of this policy, Investigators shall complete appropriate training as required under this policy; Investigators shall disclose perceived and real conflicts of interest annually and provide new or updated disclosures in a timely manner; ASN shall provide for the elimination or management of FCOI; and ASN shall make disclosures to both the PHS and to the public as required under this policy.

3. Nothing in this policy shall be construed to permit, even with disclosure, any activity that is prohibited by law.

4. For matters subject to this policy, to the extent of any conflict between this policy and provisions of the general ASN Conflict of Interest Disclosure Form, this policy shall control.

5. Nothing in this policy shall be construed to limit or abridge the authority of ASN to take such action as they deem appropriate regardless of any action or inaction by an employee of ASN.

Policy Implementation
1. Training Required:
Investigators shall complete FCOI training provided by ASN before becoming subject to this policy and then every two (2) years thereafter. ASN uses the NIH web-based training which can be accessed at: http://grants.nih.gov/grants/policy/coi/tutorial2011/fcoi.htm. Investigators must save and print the FCOI Certificate as proof of completion. Immediate training will be required if ASN revises this policy in a manner that affects the Investigator, when an Investigator is new to ASN, or because of a finding of noncompliance with this policy or a management plan, or other related misconduct.
2. Disclosure Requirement:
(a) An Investigator shall disclose any situation in which the Investigator has, or may have, a real or potential SFI as defined in this policy. Research will not proceed where a SFI is present until a determination and approval has been made pursuant to this policy.

(b) Investigators shall keep ASN informed of the Investigator’s SFIs. If ASN becomes aware of a FCOI that has not disclosed, the designated ASN official shall discuss the situation with the employee, require that a written disclosure be made as provided in this policy, and inform ASN to anticipate the receipt of a new Disclosure.

3. Disclosure Frequency:
(a) Disclosure must be made annually to ASN. If no SFI is present a Disclosure must still be submitted that states “none”. The date such annual Disclosure is due shall be set by ASN.

(b) In addition to the annual Disclosure, a new or updated Disclosure must be completed in a timely manner whenever a new or potential SFI arises or when a significant change occurs concerning an existing Disclosure.

(c) Disclosures must be made within thirty (30) days of discovery or acquiring a new SFI.

(d) Newly hired Investigators should make a Disclosure as part of their new hire employment process.

4. Review and Management:
(a) ASN shall appoint and authorize a Research Conflict of Interest Committee (Committee) of appropriate composition and skills to review the Disclosure and determine if it is a FCOI.

(b) If a determination is made that a FCOI exists, the Committee shall seek input from the Investigator and recommend to ASN a suitable action plan (Management Plan) to eliminate or manage the FCOI consistent with the objectives of this policy. The Management Plan shall provide for its periodic review and updating at least annually. If there is no reasonable way to manage a FCOI then the Investigator may be prohibited from participating in the related research until such a time as the FCOI is eliminated.

(c) Examples of conditions or restrictions that might be imposed to manage a financial conflict of interest include, but are not limited to:

(i) Public disclosure of financial conflicts of interest (e.g., when presenting or publishing the research);

(ii) For research projects involving human subjects research, disclosure of financial conflicts of interest directly to participants;

(iii) Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from the financial conflict of interest;
(iv) Modification of the research plan;

(v) Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;

(vi) Reduction or elimination of the financial interest (e.g. sale of an equity interest); or

(vii) Severance of relationships that create financial conflicts.

(d) ASN shall review the proposed Management Plan and can approve, modify, and approve, or return it to the Committee for additional work. Final review and determination must be completed prior to the expenditure of any PHS funds for the applicable research.

Violations and Sanctions

1. Sanctions:
Violations of ASN policies, including the failure to avoid a prohibited activity or disclose a conflict of interest in a timely manner, will be dealt with in accordance with applicable policies and procedures that may include disciplinary actions up to and including termination of employment.

2. Retrospective Review:
(a) ASN shall complete retrospective reviews of determinations of noncompliance with this policy within 120 days of the determination.

(b) The retrospective reviews shall be documented; such documentation shall include, but not necessarily be limited to, all of the following key elements:
1. Project number;
2. Project title;
3. PD/PI or contact PD/PI if a multiple PD/PI model is used;
4. Name of the Investigator with the FCOI;
5. Name of the entity with which the Investigator has a financial conflict of interest;
6. Reason(s) for the retrospective review;
7. Detailed methodology used for the retrospective review (e.g., methodology of the review process, composition of the review panel, documents reviewed);
8. Findings of the review; and
9. Conclusions of the review.

Based on the results of the retrospective review, if appropriate, ASN shall update the previously submitted FCOI report, specifying the actions that will be taken to manage the FCOI going forward.

(d) If bias is found, ASN is required to notify the PHS Awarding Component promptly and submit a mitigation report to the PHS Awarding Component. The mitigation report must include, at a minimum, the key elements documented in the retrospective review above and a description of the impact of the bias on the research project and ASN’s plan of action or actions taken to eliminate or mitigate the effect of the bias (e.g., impact on the research project; extent of harm
done, including any qualitative and quantitative data to support any actual or future harm; analysis of whether the research project is salvageable). Thereafter, ASN will submit FCOI reports annually. Depending on the nature of the FCOI, ASN may determine that additional interim measures are necessary with regard to the Investigator’s participation in the PHS-funded research project between the date that the financial conflict of interest or the Investigator’s noncompliance is determined and the completion of ASN’s retrospective review.

3. Clinical Research: In any case in which the Department of Health and Human Services (HHS) determines that a PHS-funded project of clinical research whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by an Investigator with a FCOI that was not managed or reported by ASN as required by this policy, ASN shall require the Investigator involved to disclose the FCOI in each public presentation of the results of the research and to request an addendum to previously published presentations.

**Institutional Reporting**

4. ASN shall provide annual and revised reports of FCOI to PHS/NIH per the applicable regulations.

5. ASN shall notify PHS/NIH of bias found in the design, conduct, or reporting of PHS/NIH funded research including whether Investigator failure to comply with this FCOI policy or management plan appears to have caused such bias.

6. Records shall be maintained for at least three (3) years from the submission of the final expenditure reports for the pertinent PHS/NIH funding or, where applicable, from other dates specified in 45 C.F.R. 75.361 (see FAQ A.11) for different situations.

7. FCOI informational requests by the public should be made to ASN. ASN shall respond to requests for FCOI information within five (5) business days as provided for under applicable regulations.

**Subrecipients**

ASN shall require subrecipient compliance with pertinent FCOI requirements as mandated by PHS regulation.

September 5, 2022